Natco faces regulatory heat in India over anticancer
This article was originally published in Scrip
Executive Summary
The drugs controller general of India, Dr Surinder Singh, is said to be mulling legal action against Natco Pharma for selling a "substandard" drug, Albupax (paclitaxel in an albumin bound nanoparticle form), which has already allegedly failed certain endotoxin tests.